Table 1.
Characteristics of the 606 patients at baseline.
| Number of patients | 606 |
|---|---|
| Mean (SD) | |
| Age (years) | 52.55 (14.90) |
| BMI | 26.65 (4.74) |
| mPASI at baseline | 15.44 (7.28) |
| Disease duration (years) | 19.44 (13.98) |
| N (%) | |
| Male | 411 (67.82) |
| Obese (BMI ≥30) | 110 (18.15) |
| PsA | 130 (21.45) |
| Difficult-site involvement | 430 (70.96) |
| Comorbidity | 326 (53.80) |
| Cardiometabolic comorbidities | 305 (50.33) |
| Hepatitis C | 4 (0.66) |
| Hepatitis B | 5 (0.83) |
| Bio-experienced | 309 (50.99) |
| Previous biologics | |
| Adalimumab | 125 (20.63) |
| Etanercept | 87 (14.37) |
| Infliximab | 10 (1.65) |
| Apremilast | 14 (2.31) |
| Secukinumab | 94 (15.51) |
| Ixekizumab | 36 (5.94) |
| Ustekinumab | 47 (7.76) |
| Guselkumab | 15 (2.48) |
| Risankizumab | 10 (1.65) |
| Tildrakizumab | 7 (1.16) |
SD, standard deviation; BMI: body mass index; PsA: psoriatic arthritis; PASI: psoriasis area and severity index; mPASI: mean PASI.